NCT07142785 Clinical Evaluation of With or Without Internal Limiting Membrane Peeling for Idiopathic Epiretinal Membrane Surgery: A Randomized Controlled Trial
| NCT ID | NCT07142785 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine |
| Condition | Idiopathic Epiretinal Membranes |
| Study Type | INTERVENTIONAL |
| Enrollment | 96 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 96 participants in total. It began in 2025-09-01 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Idiopathic epiretinal membrane (ERM) is an age-related degenerative retinal condition. One of the primary treatment approaches is vitrectomy combined with epiretinal membrane peeling. However, whether to concurrently perform internal limiting membrane (ILM) peeling remains clinically controversial. Therefore, this study aims to compare the efficacy and safety of performing versus omitting ILM peeling during idiopathic ERM surgery.
Eligibility Criteria
Inclusion Criteria: * Patients aged \>18 years presenting to our hospital within the study period. * Patients diagnosed with idiopathic epiretinal membrane (ERM) based on examination. * Patients with best-corrected visual acuity (BCVA) ≤ 0.6 or the presence of metamorphopsia. Exclusion Criteria: * Patients with secondary ERM identified during preoperative evaluation (e.g., secondary to retinal vein occlusion). * Patients with concomitant ocular diseases affecting the macula, such as macular degeneration, macular schisis, or macular atrophy. * Patients with a history of ocular trauma or previous ocular surgery (except for cataract surgery). * Patients with severe systemic diseases contraindicated for surgery. * Patients with poor compliance or concomitant psychiatric disorders. * Patients who participated in other clinical trials during the follow-up period or who were lost to follow-up.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07142785 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Idiopathic Epiretinal Membranes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07142785 currently recruiting?
Yes, NCT07142785 is actively recruiting participants. Contact the research team at yyzbzhong@zju.edu.cn for enrollment information.
Where is the NCT07142785 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT07142785 clinical trial?
NCT07142785 is sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. The trial plans to enroll 96 participants.